BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 19167854)

  • 1. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
    Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
    Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
    Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
    Wielgos T; Havel K; Ivanova N; Weinberger R
    J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography.
    Limtiaco JF; Jones CJ; Larive CK
    Anal Chem; 2009 Dec; 81(24):10116-23. PubMed ID: 19911825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
    Bigler P; Brenneisen R
    J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and highly sensitive mixed-polymeric electrokinetic chromatography system for determination of contaminants and impurities of heparin samples.
    Tripodi V; Flor S; Dobrecky C; Contin M; Lucangioli S
    Electrophoresis; 2010 Oct; 31(21):3606-12. PubMed ID: 20967770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
    Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
    J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of SAX-HPLC-CD as a heparin screening strategy.
    Chmielewski AJ; Stanley FE; Stalcup AM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2619-23. PubMed ID: 21831728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-dimensional cellulose acetate plate electrophoresis--a feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin.
    Domanig R; Jöbstl W; Gruber S; Freudemann T
    J Pharm Biomed Anal; 2009 Jan; 49(1):151-5. PubMed ID: 19062213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application.
    Hu P; Fang L; Chess EK
    Anal Chem; 2009 Mar; 81(6):2332-43. PubMed ID: 19228018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE.
    Zhang Z; Li B; Suwan J; Zhang F; Wang Z; Liu H; Mulloy B; Linhardt RJ
    J Pharm Sci; 2009 Nov; 98(11):4017-26. PubMed ID: 19642166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.
    Volpi N; Maccari F; Linhardt RJ
    Anal Biochem; 2009 May; 388(1):140-5. PubMed ID: 19232311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and purity test of heparin by NMR - a summary of two years' experience at the Medical Products Agency.
    McEwen I; Amini A; Olofsson IM
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):65-72. PubMed ID: 20223191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of dermatan sulfate and chondroitin sulfate as related substances in heparin by capillary electrophoresis.
    Bendazzoli C; Liverani L; Spelta F; Prandi M; Fiori J; Gotti R
    J Pharm Biomed Anal; 2010 Dec; 53(5):1193-200. PubMed ID: 20674212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
    Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
    Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.